Effects of daclizumab HYP on accumulation of disability exclusive of acute relapse in moderate/severe relapsing-remitting multiple sclerosis patients: A composite disability outcome from the DECIDE study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: 54d3db870914c04c47156307120db6d32da486e4
First added on: Apr 30, 2026